SCHEMBL31024377

SCHEMBL31024377

[2H]C([2H])(OCC1CCN(C(=O)c2ccc(Cl)c(N3CCC(=O)NC3=O)c2)CC1)C1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ CRBN Q96SW2 6/20 0.38
▸ DDB1 Q16531 5/20 0.38
▸ PDK1 Q15118 1/20 0.38
▸ PDK2 Q15119 1/20 0.38
▸ PDK3 Q15120 1/20 0.38
▸ PDK4 Q16654 1/20 0.38
▸ GPR119 Q8TDV5 2/20 0.37
▸ ABL1 P00519 1/20 0.37
▸ RIN1 Q13671 1/20 0.37
▸ MGLL Q99685 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ CHEK2 O96017 1/20 0.36
▸ NOTCH1 P46531 1/20 0.36
▸ MMP13 P45452 1/20 0.35
▸ ADAM17 P78536 1/20 0.35
▸ ADAMTS5 Q9UNA0 1/20 0.35
▸ TNKS O95271 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27124609 0.94 MEN1 (0.42) MEN1KMT2ACRBNDDB1PDK1
SCHEMBL31024364 0.94 MEN1 (0.42) MEN1KMT2ACRBNDDB1PDK1
SCHEMBL31024352 0.89 GPR119 (0.45) MEN1KMT2ACRBNDDB1PDK1
SCHEMBL29892557 0.89 GPR119 (0.43) MEN1KMT2ACRBNDDB1PDK1
SCHEMBL27137616 0.89 CRBN (0.39) MEN1KMT2ACRBNDDB1PDK1
SCHEMBL30014987 0.88 MGLL (0.39) MGLLTNKSPARP1PARP10TNKS2
SCHEMBL23123648 0.86 CNR1 (0.43) MEN1KMT2ACRBNDDB1PDK1
SCHEMBL31161308 0.86 CNR1 (0.43) MEN1KMT2ACRBNDDB1PDK1
SCHEMBL26099471 0.86 MEN1 (0.52) MEN1KMT2ACRBNDDB1PDK1
SCHEMBL23121362 0.85 KMT2A (0.44) MEN1KMT2ACRBNDDB1PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240261417-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2024-08-08 — — US disclosed
US-20240261418-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2024-08-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240261418-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SOS1, RAC1, RSU1 MEN1 805/4885KMT2A 4200/4885CRBN 802/4885
US-20240261417-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF RAC1, SOS1, RSU1 MEN1 920/4885KMT2A 4157/4885CRBN 606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback